Hradiste Military Area

Researchers are evaluating KBP-336, a drug designed for weekly injection, to see if it can reduce knee pain in people with osteoarthritis who are also obese. This study aims to find out if KBP-336 lowers knee pain and body weight compared to a placebo. It also explores the effects of KBP-336 on quality of life, metabolism, and safety in this group. Participants will receive either KBP-336 or a placebo once a week for six months. The trial includes regular visits every two weeks for checkups and tests. Participants are asked to keep a diary to record their symptoms and any additional pain medication they use. Throughout the study, researchers will track changes in body weight and knee pain using a standardized pain scale over 183 days. Safety and other health parameters will be monitored through clinic visits and participant diaries. The total study duration for each participant is approximately six months.